| Literature DB >> 24179828 |
Atsuo Yoshino1, Yasumasa Okamoto, Shinpei Yoshimura, Kazuhiro Shishida, Shigeru Toki, Mitsuru Doi, Akihiko Machino, Takuji Fukumoto, Hidehisa Yamashita, Shigeto Yamawaki.
Abstract
Pain is a multidimensional phenomenon. Patients with somatoform pain disorder suffer from long-lasting pain, with the pathology being closely associated with cognitive-emotional components. Differences between these patients and controls in cerebral responses to pain stimuli have been reported. However, to our knowledge, no studies of somatoform pain disorder have evaluated altered pain-related brain activation as modulated by emotional dysregulation. We examined the distinct neural mechanism that is engaged in response to two different pain intensities in a sad emotional condition, performing functional magnetic resonance imaging (fMRI) on a group of 11 somatoform pain patients and an age-matched control group. Our results showed that the ratio for low-pain intensity ratings between the sad and neutral conditions in patients was higher than in controls. They also showed significant increased activation in the anterior/posterior insula in the low pain sadness condition. Furthermore, there was specific functional connectivity between the anterior insula and the parahippocampus in patients during presentation of low-pain stimuli in the sad context. These findings suggest that a negative emotional context such as sadness contributes to dysfunctional pain processing in somatoform pain disorder. Greater sensitivity to low levels of pain in an emotional context of sadness might be an important aspect of the psychopathology of somatoform pain disorder.Entities:
Keywords: Insula; Pain; Parahippocampus; Sadness; Somatoform pain disorder; fMRI
Year: 2013 PMID: 24179828 PMCID: PMC3777689 DOI: 10.1016/j.nicl.2013.06.001
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1Schematic representation of the experimental design. Facial expressions were presented for 4 s. The same emotion was represented 4 times sequentially in different faces randomly selected. Pain stimuli were delivered while the facial stimuli were presented. The interval between the pain stimuli was randomized, with an average of 1 s. Immediately after the pain stimuli, participants were instructed to rate their average level of pain across the 8 s using a numeric rating scale (NRS) ranging from 0 (no pain at all) to 10 (worst imaginable pain). They pushed the button to stop the bar moving between 0 and 10 to rate the intensity of their pain perception.
Pain ratings by the differences of facial images.
SD, standard deviation.
*Statistically significant difference between emotions (p < 0.05).
♦Significant interaction between group and emotion (p < 0.05). Bonferroni's post hoc tests showed that the ratio between sad and neutral on low pain in patients was more highly rated than moderate pain in patients and low pain in controls (p < 0.05).
Main effect of pain.
| Brain regions | L/R | x/y/z | z-score | Cluster extent |
|---|---|---|---|---|
| ACC (BA 32) | R | 8/34/24 | 3.32 | 43 |
| ACC (BA 24) | R | 6/20/30 | 3.75 | 124 |
| ACC (BA 24) | L | − 8/6/32 | 4.17 | 152 |
| Insula | R | 42/0/− 4 | 3.40 | 24 |
| Insula | L | − 40/− 8/− 6 | 4.22 | 50 |
| Thalamus | R | 6/− 4/12 | 4.07 | 227 |
| Thalamus | L | − 8/− 4/14 | 5.21 | 259 |
| Superior frontal gyrus | ||||
| (BA9) | L | − 18/54/26 | 3.96 | 65 |
| Middle frontal gyrus | ||||
| (BA8) | L | − 34/24/48 | 4.58 | 118 |
| Inferior frontal gyrus | ||||
| (BA45) | L | − 56/8/8 | 5.63 | 392 |
| Caudate | L | − 16/14/8 | 3.69 | 21 |
| S1 (BA2) | L | − 66/− 24/34 | 4.12 | 78 |
| S2 (BA40) | R | 60/− 24/20 | 5.82 | 468 |
| S2 (BA40) | L | − 60/− 24/20 | 4.94 | 347 |
| SMA (BA6) | L | − 2/12/58 | 5.72 | 435 |
| M1 (BA4) | R | 50/2/44 | 3.99 | 114 |
| M1 (BA4) | L | − 38/− 8/62 | 4.23 | 65 |
| Middle temporal gyrus | L | − 56/− 62/6 | 3.99 | 58 |
| Superior temporal gyrus | L | − 56/4/10 | 5.63 | 81 |
Brain regions stated in MNI coordinates with activation maxima of experimentally induced p, thresholded at uncorrected p < 0.001. Minimum activation cluster size is 20 voxel.
ACC, anterior cingulate cortex; S1, primary somatosensory cortex; S2, secondary somatosensory cortex; SMA, supplementary motor area; M1, primary motor cortex.
Fig. 2BOLD-signal differences between patients with somatoform pain disorder and controls.
A–C; Group × pain × emotion interactions in the insula and the hippocampus are shown (3-way-ANOVA; BDI, STAI-S, and STAI-T scores as covariates). In patients, stronger activations were found in the moderate pain neutral and low pain sad conditions. In controls, stronger activation was found in the moderate pain sad condition.
D; The graph shows the parameter estimate of the peak coordinate as the difference of connectivity strength for low-pain stimuli in the sad condition. Anterior insula activity covaried more strongly with activity in the parahippocampus in patients.
Demographic and psychometric variables of patients and controls.
| Patients (n = 11) | Controls (n = 11) | ||
|---|---|---|---|
| Age | 40.9 ± 6.5 | 40.6 ± 6.1 | 0.1ns |
| Female/male | 6/5 | 6/5 | 0.0ns |
| Pain duration (months) | 91.0 ± 85.7 | – | – |
| Rating of clinical pain (NRS) | 7.6 ± 1.7/10 | – | – |
| Psychiatric diagnosis | |||
| Pain disorder | 11/11 | – | – |
| Current major depressive episode | 0/11 | – | – |
| Major depression in history | 5/11 | – | – |
| Generalized anxiety disorder | 3/11 | – | – |
| Other psychiatric disorders | 0/11 | – | – |
| BDI | 15.9 ± 11.1 | 4.0 ± 4.9 | 3.2 |
| STAI | |||
| State | 55.3 ± 11.3 | 37.8 ± 8.6 | 4.1 |
| Trait | 55.8 ± 11.9 | 41.4 ± 10.7 | 3.0 |
| SF-36 | |||
| Physical functioning | 84.5 ± 13.7 | 97.3 ± 3.4 | − 3.0 |
| Role physical | 45.5 ± 48.5 | 84.1 ± 23.1 | − 2.4 |
| Bodily pain | 39.5 ± 28.0 | 92.7 ± 13.4 | − 5.7 |
| General health | 33.7 ± 23.9 | 75.2 ± 14.9 | − 4.9 |
| Vitality | 38.2 ± 28.6 | 59.5 ± 12.7 | − 2.3 |
| Social functioning | 63.6 ± 21.3 | 94.3 ± 11.7 | − 4.2 |
| Role emotional | 54.5 ± 45.4 | 81.8 ± 34.6 | − 1.6 ns |
| Mental health | 35.3 ± 20.1 | 52.0 ± 10.3 | − 2.5 |
| NART | 110.1 ± 6.7 | 112.9 ± 4.3 | − 1.2 ns |
| SF-MPQ | |||
| Sensory | 12.5 ± 8.2 | – | – |
| Affective | 3.3 ± 2.5 | – | – |
| PCS | 35.5 ± 9.1 | – | – |
ns = not significant.
NRS = numeric rating scale; BDI = Beck Depression Inventory; STAI = State-Trait Anxiety Inventory; SF-36 = Short Form-36; NART = National Adult Reading Test; SF-MPQ = Short Form of the McGill Pain Questionnaire; PCS = Pain Catastrophizing Scale.
Ptwo-sided < 0.05 (two sample t-test).
Ptwo-sided < 0.01 (two sample t-test).
Ptwo-sided < 0.001 (two sample t-test).
Patients' characteristics.
| No | Medical diagnosis | Medications |
|---|---|---|
| 1 | Somatoform pain disorder | Tryptanol 75 mg, sulpiride 150 mg, loxoprofen 180 mg |
| Generalized anxiety disorder | ||
| Major depression in history | ||
| 2 | Somatoform pain disorder | Tryptanol 75 mg, clonazepam 1.5 mg |
| Major depression in history | ||
| 3 | Somatoform pain disorder | Mirtazapine 45 mg, pregabalin 75 mg, loxoprofen 180 mg, eperison 100 mg |
| 4 | Somatoform pain disorder | Nortriptyline 50 mg, clonazepam 0.5 mg, tizanidine 3 mg |
| 5 | Somatoform pain disorder | Tryptanol 75 mg |
| 6 | Somatoform pain disorder | Duloxetine 40 mg, tizanidine 3 mg |
| 7 | Somatoform pain disorder | Amoxapine 25 mg |
| 8 | Somatoform pain disorder | Tryptanol 25 mg, trazodone 25 mg |
| Major depression in history | Loxoprofen 180 mg | |
| 9 | Somatoform pain disorder | Duloxetine 20 mg, quetiapine 25 mg, clonazepam 0.5 mg, sodium valproate 400 mg |
| Generalized anxiety disorder | ||
| 10 | Somatoform pain disorder | Nortriptyline 150 mg, tizanidine 3 mg |
| Generalized anxiety disorder | ||
| Major depression in history | ||
| 11 | Somatoform pain disorder | Tryptanol 50 mg, trazodone 50 mg, carbamazepine 200 mg, clonazepam 1 mg, eletriptan 20 mg |
| Major depression in history |